36 studies were found.

1.		No longer recruiting	Anti-Angiogenesis Therapy Using Thalidomide in Patients with Waldenstrom’s Macroglobulinemia Condition: Waldenstrom Macroglobulinemia
2.		Recruiting	CC-5013 in Myelofibrosis Condition: Myelofibrosis
3.		No longer recruiting	CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma Condition: Multiple Myeloma
4.		Completed	CDC-501 therapy in relapsed or refractory multiple myeloma Condition: Multiple Myeloma
5.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
6.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
7.		Completed	Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome Conditions: HIV Infections; HIV Wasting Syndrome
8.		Completed	D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients Conditions: Fatigue; Neoplasms
9.		No longer recruiting	D.T. PACE versus High Dose Melphalan and Autologous Transplant in Patients with Previously Treated Multiple Myeloma Condition: Multiple Myeloma
10.		No longer recruiting	DTPACE followed by Tandem Transplant with MEL 200 versus MEL/DTPACE Hybrid and DTPACE Consolidation Condition: Multiple Myeloma
11.		No longer recruiting	Efficacy and safety study of CC-5013 monotherapy in subjects with myelodysplastic syndromes Condition: Myelodysplastic Syndromes
12.		No longer recruiting	A Multicenter, open-label study to evaluate the preliminary safety and efficacy of CC-5013 in the treatment of Complex Regional Pain Syndrome (CRPS) Condition: Complex Regional Pain Syndrome (RSD)
13.		No longer recruiting	Phase 1 Study OF CDC-501 in Patients with Solid Tumors Condition: Neoplasms
14.		Recruiting	A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) Condition: Multiple Myeloma
15.		Recruiting	Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas Conditions: Glioblastoma; Malignant Gliomas
16.		Completed	A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection Condition: HIV Infections
17.		No longer recruiting	A Phase II Study of Continuous versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma Condition: Multiple Myeloma
18.		Completed	A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Conditions: HIV Infections; HIV Wasting Syndrome
19.		Terminated	A phase II, randomized, open-label, controlled, dose-elevation, multicenter trial of an investigational drug for the prevention of diarrhea associated with Irinotecan/5FU/Leucovorin chemotherapy in patients with previously untreated metastatic colorectal cancer Conditions: Colorectal Neoplasms; Diarrhea
20.		No longer recruiting	Safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC) Condition: Prostate Cancer
21.		No longer recruiting	Safety and efficacy of CC-5013 monotherapy in subjects with myelodysplastic syndromes associated with a del (5q) cytogenetic abnormality Condition: Myelodysplastic Syndromes
22.		No longer recruiting	Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma Condition: Multiple Myeloma
23.		Recruiting	Study of Combination PS-341 and Thalidomide in Multiple Myeloma Condition: Multiple Myeloma
24.		Recruiting	Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Condition: Multiple Myeloma
25.		Not yet recruiting	Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma Condition: Multiple Myeloma
26.		No longer recruiting	Study of the Safety and Efficacy of CC-5013 Treatment For Patients with Myelodysplastic Syndrome Condition: Myelodysplastic Syndrome
27.		Recruiting	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Condition: Multiple Myeloma
28.		Completed	A study to access the safety/efficacy of thalidomide in the treatment of anemia in patients with Myelodysplastic Syndromes Condition: Myelodysplastic Syndromes
29.		Completed	Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects with Metastatic Malignant Melanoma. Conditions: Melanoma; Neoplasm Metastasis
30.		Completed	Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Conditions: Melanoma; Neoplasm Metastasis
31.		Completed	Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes Condition: Myelodysplastic Syndrome
32.		No longer recruiting	Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia Condition: Leukemia
33.		Suspended	Thalidomide for Multiple Myeloma Condition: Multiple Myeloma
34.		Suspended	Thalidomide-Dexamethasone for Multiple Myeloma Condition: Multiple Myeloma
35.		No longer recruiting	Total Therapy II Condition: Multiple Myeloma
36.		Recruiting	UARK 2003-33, Total Therapy III Condition: Multiple Myeloma